论文部分内容阅读
目的 :探讨普伐他汀对高脂血症患者血小板活化功能的影响。方法 :测定 3 0例高胆固醇血症和混合性高脂血症患者 (治疗组 )降脂治疗前和治疗 (普伐他汀 2 0mg/d) 4周、8周后及 3 0例健康者 (对照组 )的总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇及血小板表面激活标记物CD62p。结果 :治疗组患者CD62p较对照组明显增高 (P <0 .0 1) ,普伐他汀治疗 4周 ,8周后CD62p较治疗前明显下降 (P<0 .0 1)。结论 :普伐他汀治疗高胆固醇血症患者 ,在降脂的同时 ,可抑制血小板活性。
Objective: To investigate the effect of pravastatin on platelet activation in patients with hyperlipidemia. Methods: 30 patients with hypercholesterolemia and mixed hyperlipidemia (treatment group) were measured before and after lipid-lowering therapy (pravastatin 20 mg / d) for 4 weeks, 8 weeks and 30 healthy subjects Control group) of total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol and platelet surface activation marker CD62p. Results: CD62p in treatment group was significantly higher than that in control group (P <0.01). After treatment with pravastatin for 4 weeks, CD62p was significantly decreased (P <0.01) after 8 weeks. Conclusion: Pravastatin in patients with hypercholesterolemia, while lipid-lowering, can inhibit platelet activity.